Current FDA labels document these patterns in detail: Wegovy (semaglutide) lists nausea (44% vs 16% placebo), vomiting (25% vs 6%), diarrhea (30% vs 16%), constipation (24% vs 11%), abdominal distension and eructation, with severe GI events in 4.1% versus 0.9% placebo.[2] Zepbound (tirzepatide) lists nausea, diarrhea, vomiting, constipation, abdominal pain, dyspepsia, eructation, and gastroesophageal reflux disease among common adverse reactions, with severe GI disease as a Warnings and Precautions item.[3] Both labels include postmarketing reports of ileus, severe constipation including fecal impaction, and acute kidney injury related to dehydration from severe GI symptoms
The primary way to prevent its occurrence in the context of elective surgeries is adherence to fasting protocols
Patients experiencing such reactions should stop using Ozempic and call 999 or attend A&E immediately
Notre site Web sera de retour sous peu
Obesity and overweight [internet]
Gracias a su formacin y conocimientos especializados, los RDN pueden identificar posibles deficiencias de nutrientes y personalizar un plan de alimentacin adaptado a las necesidades especficas de su organismo
